Sellas Life Sciences Group Inc (NASDAQ: SLS) today announced heartening restructured scientific statistics from a Phase 1 investigator-sponsored scientific pilot of its foremost scientific applicant, galinpepimut-S (GPS). The applicant united with the checkpoint inhibitor nivolumab (Opdivo®) in patients with macroscopic deposits of malevolent pleural mesothelioma. The reading particulars are as […]